Nature Communications (Nov 2021)
Elevated circulating follistatin associates with an increased risk of type 2 diabetes
- Chuanyan Wu,
- Yan Borné,
- Rui Gao,
- Maykel López Rodriguez,
- William C. Roell,
- Jonathan M. Wilson,
- Ajit Regmi,
- Cheng Luan,
- Dina Mansour Aly,
- Andreas Peter,
- Jürgen Machann,
- Harald Staiger,
- Andreas Fritsche,
- Andreas L. Birkenfeld,
- Rongya Tao,
- Robert Wagner,
- Mickaël Canouil,
- Mun-Gwan Hong,
- Jochen M. Schwenk,
- Emma Ahlqvist,
- Minna U. Kaikkonen,
- Peter Nilsson,
- Angela C. Shore,
- Faisel Khan,
- Andrea Natali,
- Olle Melander,
- Marju Orho-Melander,
- Jan Nilsson,
- Hans-Ulrich Häring,
- Erik Renström,
- Claes B. Wollheim,
- Gunnar Engström,
- Jianping Weng,
- Ewan R. Pearson,
- Paul W. Franks,
- Morris F. White,
- Kevin L. Duffin,
- Allan Arthur Vaag,
- Markku Laakso,
- Norbert Stefan,
- Leif Groop,
- Yang De Marinis
Affiliations
- Chuanyan Wu
- Department of Clinical Sciences, Lund University
- Yan Borné
- Department of Clinical Sciences, Lund University
- Rui Gao
- School of Control Science and Engineering, Shandong University
- Maykel López Rodriguez
- Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland
- William C. Roell
- Lilly Research Laboratories, Eli Lilly and Company
- Jonathan M. Wilson
- Lilly Research Laboratories, Eli Lilly and Company
- Ajit Regmi
- Lilly Research Laboratories, Eli Lilly and Company
- Cheng Luan
- Department of Clinical Sciences, Lund University
- Dina Mansour Aly
- Department of Clinical Sciences, Lund University
- Andreas Peter
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Jürgen Machann
- Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich
- Harald Staiger
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Andreas Fritsche
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Andreas L. Birkenfeld
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Rongya Tao
- Division of Endocrinology, Boston Children’s Hospital, Harvard Medical School
- Robert Wagner
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Mickaël Canouil
- Inserm U1283 / CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille; University of Lille, Lille University Hospital
- Mun-Gwan Hong
- Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology
- Jochen M. Schwenk
- Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology
- Emma Ahlqvist
- Department of Clinical Sciences, Lund University
- Minna U. Kaikkonen
- A.I. Virtanen Institute for Molecular Sciences, Department of Biotechnology and Molecular Medicine, University of Eastern Finland
- Peter Nilsson
- Department of Clinical Sciences, Lund University
- Angela C. Shore
- NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital and University of Exeter Medical School, Exeter
- Faisel Khan
- Division of Systems Medicine, University of Dundee, Ninewells Hospital & Medical School
- Andrea Natali
- Department of Clinical and Experimental Medicine, University of Pisa
- Olle Melander
- Department of Clinical Sciences, Lund University
- Marju Orho-Melander
- Department of Clinical Sciences, Lund University
- Jan Nilsson
- Department of Clinical Sciences, Lund University
- Hans-Ulrich Häring
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Erik Renström
- Department of Clinical Sciences, Lund University
- Claes B. Wollheim
- Department of Clinical Sciences, Lund University
- Gunnar Engström
- Department of Clinical Sciences, Lund University
- Jianping Weng
- Department of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China
- Ewan R. Pearson
- Division of Population Health & Genomics, School of Medicine, University of Dundee
- Paul W. Franks
- Department of Clinical Sciences, Lund University
- Morris F. White
- Division of Endocrinology, Boston Children’s Hospital, Harvard Medical School
- Kevin L. Duffin
- Lilly Research Laboratories, Eli Lilly and Company
- Allan Arthur Vaag
- Steno Diabetes Center Copenhagen
- Markku Laakso
- Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland
- Norbert Stefan
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology; and Department for Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
- Leif Groop
- Department of Clinical Sciences, Lund University
- Yang De Marinis
- Department of Clinical Sciences, Lund University
- DOI
- https://doi.org/10.1038/s41467-021-26536-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 10
Abstract
Follistatin promotes in type 2 diabetes (T2D) pathogenesis in model animals and is elevated in patients with T2D. Here the authors report that plasma follistatin associates with increased risk of incident T2D in two longitudinal cohorts, and show that follistatin regulates insulin-induced suppression lipolysis in cultured human adipocytes.
